Sugi Predict

Sugi Predict / Compounds / SCHEMBL8683261

SCHEMBL8683261

SCHEMBL8683261

O=C(O)c1cc(Cl)c(F)c(F)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.44
▸ NFE2L2 Q16236 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TSHR P16473 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ AKR1C4 P17516 1/20 0.42
▸ AKR1C3 P42330 1/20 0.42
▸ AKR1C2 P52895 1/20 0.42
▸ AKR1C1 Q04828 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7006728 0.84 KEAP1 (0.42) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL8679913 0.84 KEAP1 (0.42) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL8727081 0.84 ALDH1A1 (0.41) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL30181333 0.84 ALDH1A1 (0.41) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL7187870 0.84 HPGD (0.39) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL5872828 0.83 KEAP1 (0.43) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL7070814 0.83 AKR1C2 (0.53) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL23496803 0.81 KEAP1 (0.41) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL17982184 0.81 NOTUM (0.43) KEAP1NFE2L2ALDH1A1TSHRTP53
SCHEMBL2925916 0.81 NOTUM (0.43) KEAP1NFE2L2ALDH1A1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254136-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS Redona Therapeutics, Inc. 2024-08-01 — — US disclosed
CN-116157392-A Compounds targeting RNA binding proteins or RNA modification proteins 雷多纳治疗公司 2023-05-23 — — CN disclosed
EP-4114831-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS Twentyeight-Seven, Inc. (US) 2023-01-11 — — EP disclosed
CN-104718188-B The benzamides of N- substitutions and its purposes in treating pain 基因泰克公司 2018-08-21 — — CN disclosed
US-20170002017-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 — — US disclosed
EP-2855428-A1 N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN Genentech, Inc. (US) 2015-04-08 — — EP disclosed
US-8952169-B2 N-substituted benzamides and methods of use thereof XENON PHARMACEUTICALS INC. (CA) 2015-02-10 — — US disclosed
WO-2013177224-A1 N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN GENENTECH, INC. (US) 2013-11-28 — — WO disclosed
US-20130317001-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2013-11-28 — — US disclosed
US-5777181-A 2, 4, 5-trihalogeno- and 2, 3, 4, 5-tetrahalogenobenzene derivatives BAYER AKTIENGESELLSCHAFT (DE) 1998-07-07 — — US disclosed
EP-0600317-B1 Process for the preparation of halogenated benzoic acids HOECHST AG (DE) 1997-03-12 — — EP disclosed
US-5565614-A FLUORINATION BAYER AKTIENGESELLSCHAFT (DE) 1996-10-15 — — US disclosed
US-5530158-A CHEMICAL INTERMEDIATE FOR ANTIBACTERIALS BAYER AKTIENGESELLSCHAFT (DE) 1996-06-25 — — US disclosed
US-5481032-A Process for the preparation of halogenated benzoic acids HOECHST AKTIENGESELLSCHAFT (DE) 1996-01-02 — — US disclosed
US-5362909-A Two stage fluorination BAYER AKTIENGESELLSCHAFT (DE) 1994-11-08 — — US disclosed
EP-0600317-A1 Process for the preparation of halogenated benzoic acids HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-08 — — EP disclosed
US-5200548-A Intermediates for bactericides BAYER AKTIENGESELLSCHAFT (DE) 1993-04-06 — — US disclosed
US-5072038-A Chemical intermediates for bactericides BAYER AKTIENGESELLSCHAFT (DE) 1991-12-10 — — US disclosed
US-4914123-A Acyloxythiophene derivatives BAYER AKTIENGESELLSCHAFT (DE) 1990-04-03 — — US disclosed
EP-0164619-B1 2,4,5-TRIHALO OR 2,3,4,5-TETRAHALO BENZENE DERIVATIVES AND PROCESS FOR PRODUCING THEM BAYER AG (DE) 1988-10-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002017-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SNRPD2 KEAP1 4162/4885NFE2L2 2194/4885ALDH1A1 2216/4885
US-20130317001-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SNRPD2 KEAP1 4162/4885NFE2L2 2194/4885ALDH1A1 2216/4885
US-20240254136-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS NSUN3, NSUN2, RBM3 KEAP1 1639/4885NFE2L2 2985/4885ALDH1A1 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.